Shanghai Putuo District Liqun Hospital Successfully Completes One of China's First RhythPulse®-PFA Ablation Procedures

Gender/Age: Female, 69 years old

Diagnosis: Paroxysmal Atrial Fibrillation (Left Atrial Diameter 49.5mm)

PFA Surgery Performed Under General Anesthesia Using ShineyoMedical’s 25mm Butterfly Pulsed Field Ablation Catheter: Only 36 Sets of Discharges Conducted for Ablation During the Entire Procedure; 100% Complete Isolation Achieved in All Four Pulmonary Veins, with Pacing Verification Confirming Bidirectional Conduction Block in Both Sides. Total Operation Time Was 25 Minutes, Without Any Complications Throughout, and the Procedure Was Successfully Completed.

Disappearance of Pulmonary Vein Potential After Single Discharge

Disappearance of Pulmonary Vein Potentials After Single Discharge

Atrial fibrillation is a common arrhythmia disease, often referred to as the "cardiovascular epidemic of the 21st century." In China, more than 10 million patients with atrial fibrillation are at risk of complications such as heart failure, thrombosis, and cerebral infarction. Although traditional surgical methods like radiofrequency ablation are effective, many patients are reluctant to undergo surgery due to long operation times and fear of pain.

ShineyoMedical's RhythPulse^®-PFA System is the first approved system in China that integrates multi-channel, large focal, and targeted ablation in a pulsed electric field ablation (PFA) system, primarily used for treating drug-refractory and recurrent atrial fibrillation and other types of rapid arrhythmias. Its core advantages include:

Large Focal Design:Using the world's first 10mm ring ablation catheter, a single discharge can cover a lesion area with a diameter of 10mm, improving the ablation efficiency by more than three times compared to traditional technology.

Targeted Ablation Technology:Equipped with an intelligent contact detection module, it monitors the contact status between the electrode and myocardial tissue in real time, reducing the risk of hemolysis caused by ineffective discharges, and decreasing postoperative plasma free hemoglobin content by 50%.

Clinical validation is excellent:In the clinical trial of 151 cases, the immediate success rate was 100%, and the success rate of atrial fibrillation treatment at 12 months post-operation reached 85.07%, achieving an internationally leading standard.

Cardiovascular Medicine isLiqun Hospital, Putuo District, ShanghaiKey Discipline. The department has 61 beds, including 49 general beds and 12 CCU beds. There are 16 doctors, including 2 chief physicians and 3 deputy chief physicians. It offers expert, specialized, and coronary heart disease outpatient services in the cardiology department.

Shanghai Putuo District Liqun HospitalIt is a unit certified by the National Chest Pain Center, passed the certification of "China Basic Chest Pain Center" (Basic Version) in 2019, and became a standard version certification unit in 2023. The Department of Cardiology keeps up with the forefront of discipline development and carries out interventional diagnosis and treatment technologies for coronary heart disease: coronary angiography, percutaneous transluminal coronary angioplasty, intracoronary stent implantation, intravascular ultrasound examination, and fractional flow reserve measurement, etc. It also performs temporary and permanent pacemaker implantation, and radiofrequency ablation for paroxysmal supraventricular tachycardia, atrial tachycardia, premature ventricular contractions, ventricular tachycardia, and atrial fibrillation, among other diagnostic and therapeutic techniques. It provides a rapid diagnosis and treatment channel for critically ill patients with acute chest pain as the main clinical manifestation, such as acute myocardial infarction, aortic dissection, and pulmonary embolism, enabling the "local" opening of the "culprit" vessel, further ensuring medical quality and patient safety, and meeting the diagnostic and treatment needs of different patients.